Related Experiment Video

Updated: May 26, 2026

Dried Blood Spots - Preparing and Processing for Use in Immunoassays and in Molecular Techniques
11:28

Dried Blood Spots - Preparing and Processing for Use in Immunoassays and in Molecular Techniques

Published on: March 13, 2015

Serum hyaluronic acid level does not reliably differentiate minimal and significant liver disease in chronic

Shoukat A Arain1, Sultan A Meo, Qamar Jamal

  • 1Department of Pathology, College of Medicine, Alfaisal University, PO Box 50927, Riyadh 11533, Kingdom of Saudi Arabia. sa_arain@hotmail.com

Saudi Medical Journal
|December 14, 2011
PubMed

Insights

Serum hyaluronic acid (HA) has low predictive value for significant liver disease in chronic hepatitis C (CHC) patients. High HA levels are rare, limiting its utility in treatment decisions.

Area of Science:

  • Hepatology
  • Biomarker Research
  • Diagnostic Accuracy

Background:

  • Chronic hepatitis C (CHC) poses a significant global health burden.
  • Accurate assessment of liver fibrosis and inflammation is crucial for CHC management.
  • Non-invasive biomarkers are sought to complement or replace liver biopsy.

Purpose of the Study:

  • To evaluate the predictive value of serum hyaluronic acid (HA) for liver fibrosis and inflammation in CHC.
  • To determine the diagnostic accuracy of HA in identifying significant liver disease.

Main Methods:

  • Cross-sectional study of 98 CHC patients in Pakistan.
  • Serum HA measured by ELISA.
  • Fibrosis staged (F0-F4) and inflammation graded (A0-A3).
  • Receiver operating characteristic (ROC) curve analysis used to assess diagnostic value.

Main Results:

  • Significant liver disease (F≥2 or A≥2) found in 47% of patients.
  • Mean serum HA differed significantly across disease severity groups (p=0.001).
  • Area under ROC curve for overall disease was 0.716.
  • Negative predictive value (NPV) for significant disease was 71% at HA 20 ng/mL.
  • Positive predictive value (PPV) reached 85% at 60 ng/mL and 100% at 120 ng/mL, observed in only 15% and 10% of patients, respectively.

Conclusions:

  • Serum HA demonstrates a low NPV for significant liver disease in CHC.
  • Acceptable PPV for HA was observed only in a small patient subset.
  • Hyaluronic acid is unlikely to be a reliable marker for guiding CHC treatment decisions.
Abstract

More Related Videos

Immunofluorescence to Monitor the Cellular Uptake of Human Lactoferrin and its Associated Antiviral Activity Against the Hepatitis C Virus06:28

Immunofluorescence to Monitor the Cellular Uptake of Human Lactoferrin and its Associated Antiviral Activity Against the Hepatitis C Virus

Published on: October 1, 2015

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy07:10

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy

Published on: June 18, 2020

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Ultrasound II: Endoscopic Ultrasound and FibroScan01:25

Ultrasound II: Endoscopic Ultrasound and FibroScan

Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...